Given the pivotal role of PPARα in liver lipid homeostasis and the treatment of fenofibrate, severe as a PPARα agonist, against cholestasis-induced hepatic injury [6], the expression of APOA2 and PPARα was detected by western blotting to verify the relationship between ICP and control groups. The gene discussed is PPARA; the disease is cholestasis.